ABC Landline Story “How pineapples could protect piglets from infection”

Diarrhoea can be deadly in pig farming. Scour, as it’s called in the industry, kills tens of thousands of piglets every year. It’s traditionally been treated with antibiotics, but a Queensland scientist has developed a powerful, natural alternative from an extract found in pineapple stems

The full story on Anatara and Detach™ was featured on Landline, today (19/03/17) and can be viewed online here.

Anatara to feature on ABC’s Landline

Very excited that the story of Anatara Lifesciences and our anti-infective product, Detach™ will feature on ABC’s Landline program this Sunday, March 19 at 12pm.

Make sure you tune into see how we plan to help pig farmers across the globe! #anataralifesciences #detach™ #fightpigscour #AMR

View the promotional video here.

Appendix 4D Half-Year Report

Anatara Lifesciences is pleased to release its Appendix 4D Interim Financial Report for the half year ended 31 December 2016.

Please click here to view the ASX announcement.

Anatara receives second Zoetis payment

Anatara Lifesciences is pleased to announce that it has received a second payment under the exclusive Research Evaluation and License Option Agreement with the global animal health company, Zoetis Inc., to explore the utility of Detach™ a non-antibiotic anti-infective product, for use in food production animals.

Please click here to view the ASX announcement.

Anatara 4C Quarterly Financial Report

Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the quarter ended 31 December 2016.

Please click here to view the ASX announcement.

NDF Research Research & Valuation Report

NDF Research’s Initiation of Coverage Research & Valuation Report

NDF Research has released its first research and valuation report on Anatara Lifesciences (ANR). The report valued Anatara at $2.22 base case and $5.94 optimistic case using a DCF approach, with a target price of $4.00 sitting at around the midpoint of the valuation range.

Please click here to view the report.

Anatara Investor Update

Anatara Lifesciences is pleased to release its latest investor presentation and market update that will be delivered to investors over the next two weeks by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.

Please click here to view the ASX announcement and presentation.

Annual General Meeting Results

Anatara Lifesciences is pleased to announce the following results from the Annual General Meeting held on 15th November 2016.

At today’s Annual General Meeting all Resolutions put to Shareholders were passed unanimously on a show of hands.

Please click here to view the ASX announcement.

Chairman’s Address and AGM Presentation

Anatara Lifesciences is pleased to release the presentation and Chairman’s address provided to shareholders at the Annual General Meeting held on 15th November 2016.

Please click here to view the AGM presentation.

Please click here for a copy of the Chairman’s Address.

Appendix 4C Quarterly Financial Report

Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the quarter ended 30 September 2016.

Please click here to view the ASX announcement.

NEW Wilsons Research & Valuation Report

Wilsons has released its latest research and valuation report on Anatara Lifesciences (ANR). The report maintained a BUY rating and 12 month price target of $1.75 per share.

Please open the attached PDF to view the report.

Appendix 3B – New issue announcement

Anatara Lifesciences is pleased to release its Appendix 3B – New issue announcement, for the release of 12,746,095 fully paid ordinary shares from voluntary escrow.

Please click here to view the ASX announcement.

Notice of General Meeting, Proxy Form & Appendix 4G

Anatara Lifesciences is pleased to release its Notice of General Meeting, Proxy Form and Appendix 4G and Corporate Governance Statement for shareholders.

Please click here for the Notice and Proxy Form, and here for the Appendix 4G and Corporate Governance Statement.

Annual Report to Shareholders

Anatara is pleased to release its 2016 Annual Report to its shareholders.

Please click here for the ASX announcement.

Anatara receives R&D tax refund

Anatara Lifesciences is pleased to announce that it has received $420,460 from the Australian Tax Office for the Research and Development (R&D) Tax Incentive. This refund is from Anatara’s 2014-15 research activities and future refunds will increase significantly. The company is in the process of finalising its 2015-16 tax claim.

Please click here for the ASX annnouncement.

Anatara Investor Presentation

Anatara Lifesciences is pleased to release its latest institutional roadshow presentation and market update that will be delivered to investors over the next two weeks by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.

Please click here to view the ASX announcement and presentation.

Release of Shares from Voluntary Escrow

Anatara Lifesciences is pleased to announce that in accordance with Listing Rule 3.10A, Anatara Lifesciences Limited advises that 12,746,095 fully paid ordinary shares will be released from escrow on Sunday 16 October 2016.

Please click here to view the ASX announcement.

Anatara Achieves Major Milestone – APVMA Submission

Anatara Lifesciences is pleased to announce that it has lodged its application for approval to register Detach™ with the Australian Pesticides and Veterinary Medicines Authority (APVMA). Detach™ is a natural, non-antibiotic alternative for the control of diarrhoea in piglets.

Please click here to view the ASX announcement.

Appendix 3Z – Final Directors Interest Notice

Anatara Lifesciences released an Appendix 3Z – Final Director’s Interest Notice, to the ASX on 26th September 2016.

Please click here to view the ASX announcement.

Successful Completion of Target Safety Study

Anatara Lifesciences is pleased to announce the successful completion of its pivotal Target Animal Safety (TAS) Study for Detach™, the Company’s lead product for the control of diarrhoea in piglets.

Please click here to view the ASX announcement.

Appendix 4E and Financial Report

Anatara Lifesciences today released its Appendix 4E and annual financial report for the year ending 30th June 2016.

Please click here to view the ASX announcement.

Amended Appendix 4C

Anatara Lifesciences today released its amended Appendix 4C Quarterly Financial Report for the fourth quarter ended 30 June 2016.

Please click here to view the ASX announcement.

Appendix 4C – 4th Quarter

Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the fourth quarter ended 30 June 2016.

Please click here to view the ASX announcement.

Anatara Lifesciences features in Bioshares

Bioshares has featured Anatara Lifesciences (ANR) in its latest edition. The article provided a Speculative Buy Class B recommendation.

Bioshares delivers independent investment research to investors on Australian biotech, pharma and healthcare companies.

Please click here to view the article.

NEW Wilson HTM Research & Valuation Report

Wilson HTM has released its latest research and valuation report on Anatara Lifesciences (ANR). The report maintained a Speculative BUY rating and price target of $1.75 per share.

Please open the attached PDF to view the report.

Anatara Investor Presentation and Update

Anatara Lifesciences is pleased to release its most recent investor presentation and market update.

Please click here to view the ASX announcement and presentation.

Anatara interviewed for The CEO Sessions

Anatara Lifesciences is pleased to release a copy of Dr Mel Bridges, CEO & Chairman, recent interview with the Financial News Network (FNN) as part of the ASX The CEO Sessions in Sydney on 21st June 2016.

Please click here to view the FNN interview and corresponding ASX presentation.

Appendix 3Y – Change of Director’s Interest Notice

Anatara Lifesciences released an Appendix 3Y – Change of Director’s Interest Notice, to the ASX on 1st July 2016.

Please click here to view the ASX announcement.

Appendix 3Y – Change of Director’s Interest Notice

Anatara Lifesciences released an Appendix 3Y – Change of Director’s Interest Notice, to the ASX on 29th June 2016.

Please click here to view the ASX announcement.

Anatara Expands Executive Team

Anatara Lifesciences announces changes to its management team, including the retirement of Dr Paul Schober as CEO, transition of Dr Mel Bridges into a combined CEO / Chairman role as well as the appointment of Dr Mike West as COO and Ms Kylie Davis as Clinical Trials Manager.

Please click here to view the ASX announcement.

Anatara Trial Update

Anatara Lifesciences wishes to announce it has voluntarily terminated the third efficacy study in Australia for its lead product Detach.

Please click here to view the ASX announcement.

Anatara Investor Presentation

Anatara Lifesciences is pleased to release a copy of the presentation that Chairman, Dr Mel Bridges, will be presenting at both the Finance News Network “The CEO Sessions” and the Gold Coast Investment Showcase this week.

Please click here to view the ASX announcement.

Anatara Market Update – New Trials Commence

Anatara Lifesciences is pleased to release its latest market update to its investors and to announce the commencement of two new trials that will support its application to register Detach™ for sale in Australia with the Australian Pesticides and Veterinary Medicines Authority (APVMA) and overseas.

Please click here to view the ASX announcement.

NEW Wilson HTM Research and Valuation Report

Wilson HTM has released its latest research and valuation report on Anatara Lifesciences (ANR). The report maintained a Speculative BUY rating and a new price target of $1.75 per share.

Please open the attached PDF to view the report.

Appendix 3Y – Change of Director’s Interest Notice

Anatara Lifesciences released an Appendix 3Y – Change of Director’s Interest Notice, to the ASX on 27th April 2016.

Please click here to view the ASX announcement.

Appendix 4C and Updated Cash Balance

Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the third quarter ended 31 March 2016.

Please click here to view the ASX announcement.

Anatara Milestone and Market Update

Anatara Lifesciences is pleased to release its most recent milestone and market update to its investors.

Please click here to view the ASX announcement.

Appendix 3B

Anatara Lifesciences has released an Appendix 3B – New issue announcement, application for quotation of additional securities and agreement.

Please click here to view the ASX announcement.

Appendix 4D

Anatara Lifesciences is pleased to release its Appendix 4D Interim Financial Report for the half year ended 31 December 2015.

Please click here to view the ASX announcement.

Anatara CSO interviewed for the CommSec Executive Series

CommSec’s Tom Piotrowski speaks with Anatara Lifesciences (ANR) Chief Scientific Officer, Dr Tracey Mynott about its non-antibiotic treatment for gastrointestinal diseases in production animals.

Click here to view the interview.

Investor Update and Managing Director Appointment

Anatara Lifesciences is pleased to release its most recent investor presentation and market update, and to announce that Dr Paul Schober has been appointed as Managing Director effective today.

Please click here to view the ASX announcement and investor presentation.

Appendix 4C – 2nd Quarter

Appendix 4C Financial Report

Anatara Lifesciences has released its Appendix 4C Financial Report, for the 2nd quarter ended 31 December 2015, to the market today.

Please click here to view the ASX announcement.

NEW Wilson HTM Anatara Research & Valuation Report

Wilson HTM has released its fourth research and valuation report on Anatara Lifesciences (ANR). The report maintained a Speculative BUY rating and increased price target of $1.82 per share.

Please open the attached PDF to view the report.

Anatara Announces Exclusive Research Evaluation and License Option Agreement with Zoetis

Anatara Lifesciences today announced that it has signed an exclusive evaluation and license option agreement with the leading global animal health company Zoetis Inc. for Detach™, Anatara’s non-antibiotic anti-infective product.

Key points:
· Anatara signs an exclusive evaluation and license option agreement with the global animal health company, Zoetis Inc. to explore the utility of Detach™ a non-antibiotic anti-infective product, for use in food production animals
· Detach™ has the potential to play a part as an alternative to traditional antibiotics to control infections in farm animals, as public health officials worldwide seek strategies to combat antimicrobial resistance
· Agreement grants Zoetis an exclusive option to license Detach™ for development and marketing worldwide with Anatara retaining rights to Australia and New Zealand

Please click here to read the ASX announcement.

Appendix 3B – Anatara Executive Option Plan

Anatara Lifesciences has released an Appendix 3B – New issue announcement, application for quotation of additional securities and agreement.

Please click here to view the ASX announcement.

Wilson HTM – ANR Research & Valuation Report

Wilson HTM has released its third research and valuation report on Anatara Lifesciences (ANR). The report maintained a Speculative BUY rating and a price target at $1.18 per share.

Please open the attached PDF to view the report.

Anatara features in the latest edition of Bioshares

Bioshares has featured Anatara Lifesciences (ANR) in its latest edition. The article provided a Speculative Buy recommendation.

Bioshares delivers independent investment research to investors on Australian biotech, pharma and healthcare companies.

Please open the attached PDF to view the report.

Appendix 3B

Anatara Lifesciences has released an Appendix 3B – New issue announcement, application for quotation of additional securities and agreement.

Please click here to view the ASX announcement.

Annual General Meeting Results

Anatara Lifesciences is pleased to announce the following results from the Annual General Meeting held on 11th November 2015.

At today’s Annual General Meeting all Resolutions put to Shareholders were passed unanimously on a show of hands.

Please click here to view the ASX announcement.

Annual General Meeting Presentation

Anatara Lifesciences is pleased to release the presentation provided to shareholders at the Annual General Meeting held on 11th November 2015.

Please click here to view the AGM presentation.

Chairman’s Address to Shareholders

The following Chairman’s address was made to Anatara Lifesciences shareholders at the Annual General Meeting held on 11th November 2015.

Please click here for a copy of the Chairman’s Address.

Appendix 4C – 1st Quarter

Appendix 4C Financial Report

Anatara Lifesciences has released its Appendix 4C Financial Report, for the 1st quarter ended 30 September 2015, to the market yesterday.

Please click here to view the ASX announcement.

Notice of Annual General Meeting and Proxy Form

Anatara Lifesciences is pleased to release its Notice of Annual General Meeting and Proxy Form to shareholders.

Please click here to view the ASX announcement.

Market Update Presentation

Trial Results Support Strong Partnering Interest

Anatara Lifesciences is pleased to release its market update presentation. Executives of the company will be presenting to brokers, analysts and institutional investors over the next two weeks on the company’s progress and track record in delivering against key milestones.

Please click here to view the ASX announcement and investor presentation.

Appendix 3G

Anatara Lifesciences has released an Appendix 3G – Key to Disclosures – Corporate Governance Council Principles and Recommendations.

Please click here to view the ASX announcement.

Anatara Annual Report 2015

Anatara Lifesciences is pleased to release its Annual Report 2015 to shareholders.

Please click here to view the report.

Wilson HTM – ANR Research & Valuation Report

Wilson HTM has released its second research and valuation report on Anatara Lifesciences (ANR). The report provided a Speculative BUY rating and a price target at $1.18 per share.

Please open the attached PDF to view the report.

Appendix 3B

Anatara Lifesciences has released an Appendix 3B – New issue announcement, application for quotation of additional securities and agreement.

Please click here to view the ASX announcement.

Anatara Reports Second Successful Detach™ Trial

Anatara Lifesciences is pleased to announce positive results from its latest Australian field trial of Detach™, a non-antibiotic natural therapy to prevent and treat diarrhoea (also known as scour) in piglets.

Please click here to view the ASX announcement.

Preliminary Final Report

The results for Anatara Lifesciences Limited for the year ended 30 June 2015 are as follows:

Please click here to view the ASX announcement.

Cleansing Notice and Appendix 3B

Appendix 3B

Anatara Lifesciences has today released a Cleansing Notice – Placement and an Appendix 3B – New issue announcement, application for quotation of additional securities and agreement.

Please click here to view the ASX announcement.

Anatara Forges Industry & Research Alliance with Pork CRC

Anatara Lifesciences is pleased to announce it has signed a Commercial Collaboration Agreement with the Pork Cooperative Research Centre (Pork CRC). The CRC will provide Anatara with services to locate key clinical trial sites and ongoing test sites, assist with the APVMA approval of its lead therapy, DetachTM, and promote the results of these trials.

Please click here to view the ASX announcement.

Anatara General Meeting Results

Anatara Lifesciences is pleased to announce the following results from the General Meeting held on 10th August 2015.

At today’s General Meeting all Resolutions put to Shareholders were passed unanimously on a show of hands.

Please click here to view the ASX announcement.

Appendix 3B

Appendix 3B

Anatara Lifesciences has today released an Appendix 3B – New issue announcement, application for quotation of additional securities and agreement.

Please click here to view the ASX announcement.

Appendix 4C – 4th Quarter

Appendix 4C Financial Report

Anatara Lifesciences has released its Appendix 4C Financial Report, for the 4th quarter ended 30 June 2015, to the market today.

Please click here to view the ASX announcement.

Anatara closes heavily subscribed Share Purchase Plan (SPP)

Anatara Lifesciences is pleased to announce it has raised $2million through a significantly subscribed Share Purchase Plan.

Please click here to view the ASX announcement.

Notice of General Meeting

Anatara Lifesciences has today released a Notice of General Meeting – to be held on Monday 10th August 2015 at 11am at McCullough Robertson, Level 11, 66 Eagle Street, Brisbane.

Please click here to view the ASX announcement.

Appendix 3B

Anatara Lifesciences has today released an Appendix 3B – New issue announcement, application for quotation of additional securities and agreement.

Please click here to view the ASX announcement.

Placement Cleansing Notice

Anatara Lifesciences has today released a Cleansing Notice – Placement.

Please click here to read the ASX Announcement.

Notice of Despatch of Share Purchase Plan Offer Materials

Anatara Lifesciences has released a Notice of despatch of share purchase plan offer materials.

Please click here to read the ASX Announcement

Anatara raises $7million, launches Share Purchase Plan to speed development of Detach™.

Anatara raises $7million, launches Share Purchase Plan to speed development of Detach™.

Please click here to read the ASX announcement.

Successful Capital Raising

Anatara Lifesciences Limited announces that it has completed a first tranche placement of approximately 5.64 million shares to institutional and sophisticated investors at an issue price of $0.78 per share to raise $4.4 million.

Please click here to view the ASX announcement.

Cleansing Notice – Share purchase plan

Anatara will make offers to issue ordinary shares under a share purchase plan.

Please click here to view the ASX Announcement.

Anatara Lifesciences Ltd – Trading Halt

The securities of Anatara Lifesciences have been placed in a trading halt, at the request of the company, pending the release of an announcement.

Please click here to view the ASX Announcement.

Anatara Commences Second Detach™ Trial

Anatara Lifesciences is pleased to announce it has begun its second pivotal field trial of its lead product Detach™, a non-antibiotic, natural therapy to prevent and treat diarrhoea in weaned pigs.

Please click here to view the ASX announcement.

Investor Update – Positive News Flow

Anatara Lifesciences has released its latest investor update to the Australian Securities Exchange.

Please click here to view the ASX announcement.

Anatara features in the latest edition of Bioshares

Bioshares has featured Anatara Lifesciences (ANR) in its latest edition. The article provided a Speculative Buy recommendation.

Please open the attached PDF to view the report.

Appendix 3B

Anatara Lifesciences has released its Appendix 3B – New issue announcement, application for quotation of additional securities and agreement.

Please click here to view the ASX announcement.

Release of Shares from Mandatory and Voluntary Escrow

Anatara Lifesciences is pleased to announce that in accordance with Listing Rule 3.10A, Anatara Lifesciences advises that 8,170,000 fully paid ordinary shares will be released from escrow on Friday 8 May 2015.

Please click here to view the ASX announcement.

Appendix 4C Interim Financial Report

Anatara Lifesciences has released its Appendix 4C Interim Financial Report, for the 3rd quarter ended 31 March 2015, to the market today.

Please click here to view the ASX announcement.

Anatara Investor Update – Milestone Progress

Anatara has released its latest investor presentation to the Australian Securities Exchange.

Please click here to view the presentation.

Anatara Strengthens Board and Executive Team

Anatara Lifesciences is pleased to announce the appointment of two new members to its executive management team, and strengthens the board with a new non-executive director.

Please click here to view the announcement.

Appendix 4D Interim Financial Report

Anatara Lifesciences has released its Appendix 4D Interim Financial Report, for the Half Year ended 31 December 2014, to the market today.

Please click here to view the ASX announcement.

Anatara Reports Successful Detach™ Trial Results

Anatara Lifesciences is pleased to announce positive results from the first Australian field trial of its lead product Detach™, a non-antibiotic natural product to prevent and treat diarrhoea in piglets.

Please click here to view the announcement.

Wilson HTM – ANR Research & Valuation Report

Wilson HTM today released a research and valuation report on Anatara Lifesciences (ANR). The report initiated a Speculative BUY rating and a price target of 60 cps.

Bull case valuations can push north of $2.50 per share if project success and international marketing partners are delivered over the next few years.”

Please open the attached PDF to view the report.

Anatara begins field trials of Detach™ to support registration

Anatara Lifesciences is pleased to announce it has begun the first pivotal field trial of its lead product Detach™, a non-antibiotic, natural product to prevent and treat diarrhoea in piglets.

Please click here to view the announcement.

Anatara investor presentation

Anatara has released its latest investor presentation to the Australian Securities Exchange.

Please click here to view the presentation.

Anatara Lifesciences welcomes Antibiotic Awareness Week

BRISBANE, November 19, 2014: Anatara Lifesciences, a company developing non-antibiotic treatments for gastrointestinal diseases in animals and humans, has welcomed Antibiotic Awareness Week in Australia to increase awareness around the threat to human health of antibiotic resistance.

Antibiotic Awareness Week is part of a global initiative to raise awareness about antibiotic resistance and promote the responsible use of antibiotics. It urges that the “miracle” of antibiotics be preserved and warns that “no action today, no cure tomorrow”.

Overuse of antibiotics in humans and animals has led to bacteria developing resistance to medicines and becoming so-called “super bugs” that make illnesses harder to treat.

Around 80% of antibiotics in the US are used in animal production.

Anatara Lifesciences has developed a non-antibiotic therapy for diarrhoea called DetachTM that will help reduce the use of antibiotics in pigs.

“Antimicrobial resistance is a threat to human health that is increasingly becoming a major issue for authorities,” Anatara Chairman Mel Bridges said.

“Awareness is growing and with that will come demands from consumers, health authorities and farmers for non-antibiotic therapies for production animals.”

Detach works by stopping bacteria from attaching to the lining of the intestine, as well as blocking the action of their toxins, the underlying cause of diarrhoea. It works differently to antibiotics in that it doesn’t try to kill bacteria and instead lets them pass through the intestine harmlessly.

The Australian Commission on Safety and Quality in Health Care is working with key partners from human health, animal health and agriculture to raise awareness about the problem of antibiotic resistance.

Antibiotic Awareness Week is from November 17 to November 23.

Anatara features on Financial Review Sunday program

Anatara has featured on one of Australia’s leading business television programs, Financial Review Sunday.

The program was about companies listing on the Australian Securities Exchange (ASX) in 2014 and included an interview with Anatara’s chief scientific officer and co-founder Dr Tracey Mynott.

Dr Mynott explained how stringent regulatory requirements necessary to list on the ASX validates the company and provides confidence to potential overseas partners.

To watch the video click here.

 

Anatara newsletter

Anatara has released its first newsletter after successfully listing on the Australian Securities Exchange.

Please click here to view the newsletter.

Anatara manufacturing, clinical trial and European SME status update

Anatara Lifesciences is pleased to announce it has completed its first pilot manufacturing runs of Detach™ and will now initiate manufacture required for registration purposes under the Australian Pesticides and Veterinary Medicines Authority’s (AVPMA’s) product registration approval process.

Please click here to view the announcement.

Anatara listing day video

ASX confirms Anatara admission to Official List

Anatara Lifesciences has been added to the ASX’s Official List and it’s shares are due to commence trading on Thursday, October 16, 2014.

For more read here.

Float Watch in The Australian

Anatara Lifescience’s impending listing on the Australian Securities Exchange has been discussed in the Float Watch section of Australia’s only daily broadsheet newspaper The Australian.
Analyst Tim Morris, from wise-owl.com, notes that the global appetite for pork is strong as Anatara develops Detach™, our non-antibiotic treatment for diarrhoea in pigs.
He says Anatara controls intellectual property associated with an earlier formulation of Detach™ and that Anatara has further developed the therapy in preparation for field trials.
Read more here.

Media Release – Anatara Lifesciences raises $7 million in oversubscribed offer

BRISBANE, 7 October 2014: Anatara Lifesciences is pleased to announce it has raised $7 million through an oversubscribed Initial Public Offering that has now closed.

The company, which is developing non-antibiotic medicines for the treatment and prevention of diarrhoea in animals and humans, offered 14 million shares at $0.50 a share.

Anatara expects the shares to begin trading on the Australian Securities Exchange the week beginning October 13th, with the company opening with a market capitalisation of $18,875,000. The assigned ASX code is ANR.

“The response by investors to the offering has been fantastic,” Anatara Chairman and Co-Founder Dr Mel Bridges said.

“We look forward to delivering on the enthusiasm and faith investors have shown in supporting the company and its planned future. The fact that the lead compound is derived from pineapple stems, a natural and safe resource, and addresses a significant area of unmet medical need, seems to have resonated with investors,” Dr Bridges added.

Anatara’s lead product, DetachTM, is a non-antibiotic therapy to treat and prevent diarrhoea. The company is focused on commercialising DetachTM initially for use in pigs, ahead of expanding its use to other livestock, and then developing it for use in humans.

Health authorities around the world are moving to limit the use of antibiotics in animal production as their overuse contributes to the rise of antibiotic-resistant bacteria, so-called superbugs that threaten human health.

Anatara’s objectives include:

  • Registration of DetachTM for use in pigs in Australia and the European Union
  • Registration of DetachTM for use in pigs in the United States
  • Development of DetachTM for humans

The IPO was led by Wilson HTM with co-manager Peloton Capital and legal advisers McCullough Robertson.

 

Anatara’s share market listing in the news

Anatara’s Chairman Mel Bridges conducted an interview recently with the Australian Associated Press which published an article that was widely reproduced across many media outlets.

The article highlighted that Anatara was raising $7 million in an initial public offering and would list on the Australian Securities Exchange.

It noted that Anatara’s lead product, DetachTM is a non-antibiotic medicine made from an extract from pineapple roots to treat and prevent diarrhoea in food production animals and planned to be first used in pigs.

The article was published on numerous widely-read news websites including The Australian, The Age, The Sydney Morning Herald, The Herald Sun, and The Daily Telegraph.

Obama Administration acts to combat antimicrobial resistance

US President Barack Obama has issued an Executive Order that aims to combat the rise of antibiotic resistant bacteria that represent a serious threat to public health and the economy.

It says the US Federal Government will work domestically and internationally to “detect, prevent, and control illness and death related to antibiotic-resistant infections by implementing measures that reduce the emergence and spread of antibiotic-resistant bacteria and help ensure the continued availability of effective therapeutics for the treatment of bacterial infections”.

Measures to tackle antimicrobial resistance include eliminating “the use of medically important classes of antibiotics for growth promotion purposes in food-producing animals”.

The Executive Order can be found here.

A report to the President on combating antibiotic resistance by the President’s Council of Advisors on Science and Technology can be found here.

Anatara Lifesciences in The Australian newspaper

The Anatara team met senior business journalist Tim Boreham from The Australian newspaper recently to brief him on Anatara and our plans. He notes we’re raising $7 million from investors and that we’re intending to conduct new trials to get Detach re-registered in Australia. He suggests people read our prospectus when it’s lodged.

Read more »

Pigs poo and pineapples could change the world

Anatara’s chief scientific officer Dr Tracey Mynott was interviewed by ABC Radio Brisbane about how DetachTM was created and how treating diarrhoea in pigs could lead to treatments for humans.

To listen to the interview, click here.